The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

Pflugers Archiv European Journal of Physiology

Volumn 454, Issue 6, 2007, Pages 971-976

  Wang, Ping ^a   Van Greevenbroek, Marleen M J ^b   Bouwman, Freek G ^a   Brouwers, Martijn C G J ^b   Van Der Kallen, Carla J H ^b   Smit, Egbert ^a   Keijer, Jaap ^c   Mariman, Edwin C M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

HDL cholesterol; Insulin resistance; NAD metabolism; Triglycerides; Visceral adiposity

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NICOTINAMIDE ADENINE DINUCLEOTIDE; TRIACYLGLYCEROL; VISFATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NUCLEOTIDE METABOLISM; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADIPOSITY; ADULT; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, HDL; CYTOKINES; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIGLYCERIDES;

EID: 34548315745     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-007-0262-y     Document Type: Article

References (23)

1. Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430
2. Berndt J, Kloting N, Kralisch S et al (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911-2916
3. Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165-3170
4. Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299
5. Dogru T, Sonmez A, Tasci I et al (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24-29
6. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437
7. Wang T, Zhang X, Bheda P, Revollo JR, Imai SI, Wolberger C (2006) Structure of Nampt/PBEF/visfatin, a mammalian NAD(+) biosynthetic enzyme. Nat Struct Mol Biol 13:661-662
8. Rongvaux A, Shea RJ, Mulks MH et al (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225-3234
9. Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279:50754-50763
10. Carmena R, Ascaso JF, Real JT (2001) Impact of obesity in primary hyperlipidemias. Nutr Metab Cardiovasc Dis 11:354-359
11. Keulen ET, Voors-Pette C, de Bruin TW (2001) Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 14:357-363
12. Brouwers MC, Bilderbeek-Beckers MA, Georgieva AM, van der Kallen CJ, van Greevenbroek MM, de Bruin TW (2007) Fatty liver is an integral feature of familial combined hyperlipidemia: relation with fat distribution and plasma lipids. Clin Sci (Lond) 112:123-130
13. Durnin JV, Womersley J (1974) Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32:77-97
14. Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE (2001) Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord 25:1346-1351
15. Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63
16. Smith J, Al-Amri M, Sniderman A, Cianflone K (2006) Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol (Oxf) 65:667-672
17. Ziegler M (2000) New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 267:1550-1564
18. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099-45107
19. Takahashi Y, Tanaka A, Nakamura T et al (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65:1099-1104
20. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20:1253-1268
21. Linsel-Nitschke P, Tall AR (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4:193-205
22. Kitani T, Okuno S, Fujisawa H (2003) Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544:74-78
23. Su AI, Wiltshire T, Batalov S et al (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101:6062-6067